Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease

Journal of Immunology

Volumn 186, Issue 2, 2011, Pages 1131-1139

  Croker, Ben A ^a,b,c   Lewis, Rowena S ^a   Babon, Jeff J ^a,b   Mintern, Justine D ^a   Jenne, Dieter E ^d   Metcalf, Donald ^a,b   Zhang, Jian Guo ^a   Cengia, Louise H ^a   O'Donnell, Joanne A ^a   Roberts, Andrew W ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; FAS LIGAND; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUKOCYTE ELASTASE; MYELOBLASTIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN TYROSINE PHOSPHATASE SHP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; IMMUNOREGULATION; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN INFLAMMATION;

ANIMALS; AUTOIMMUNE DISEASES; BONE MARROW CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NEUTROPHILS; PARACRINE COMMUNICATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN DISEASES; TOLL-LIKE RECEPTORS;

EID: 79251545809     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002702     Document Type: Article

References (41)

1. Beutler, B. 2009. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol. Rev. 227: 248-263.
2. Croker, B. A., B. R. Lawson, S. Rutschmann, M. Berger, C. Eidenschenk, A. L. Blasius, E. M. Moresco, S. Sovath, L. Cengia, L. D. Shultz, et al. 2008. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc. Natl. Acad. Sci. USA 105: 15028-15033.
3. Koo, G. C., H. Rosen, A. Sirotina, X. D. Ma, and L. D. Shultz. 1993. Anti-CD11b antibody prevents immunopathologic changes in viable moth-eaten bone marrow chimeric mice. J. Immunol. 151: 6733-6741.
4. Green, M. C., and L. D. Shultz. 1975. Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology. J. Hered. 66: 250-258.
5. Shultz, L. D., D. R. Coman, C. L. Bailey, W. G. Beamer, and C. L. Sidman. 1984. "Viable motheaten," a new allele at the motheaten locus. I. Pathology. Am. J. Pathol. 116: 179-192.
6. Shultz, L. D., P. A. Schweitzer, T. V. Rajan, T. Yi, J. N. Ihle, R. J. Matthews, M. L. Thomas, and D. R. Beier. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73: 1445-1454.
7. Tsui, H. W., K. A. Siminovitch, L. de Souza, and F. W. Tsui. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4: 124-129.
8. Yu, C. C., H. W. Tsui, B. Y. Ngan, M. J. Shulman, G. E. Wu, and F. W. Tsui. 1996. B and T cells are not required for the viable motheaten phenotype. J. Exp. Med. 183: 371-380.
9. Thrall, R. S., S. N. Vogel, R. Evans, and L. D. Shultz. 1997. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am. J. Pathol. 151: 1303-1310.
10. Zhang, J., A. K. Somani, and K. A. Siminovitch. 2000. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. 12: 361-378.
11. Abu-Dayyeh, I., M. T. Shio, S. Sato, S. Akira, B. Cousineau, and M. Olivier. 2008. Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif. PLoS Negl. Trop. Dis. 2: e305.
12. Kessenbrock, K., L. Fröhlich, M. Sixt, T. Lämmermann, H. Pfister, A. Bateman, A. Belaaouaj, J. Ring, M. Ollert, R. Fässler, and D. E. Jenne. 2008. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J. Clin. Invest. 118: 2438-2447.
13. Lieschke, G. J., D. Grail, G. Hodgson, D. Metcalf, E. Stanley, C. Cheers, K. J. Fowler, S. Basu, Y. F. Zhan, and A. R. Dunn. 1994. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84: 1737-1746.
14. Tapley, P., N. K. Shevde, P. A. Schweitzer, M. Gallina, S. W. Christianson, I. L. Lin, R. B. Stein, L. D. Shultz, J. Rosen, and P. Lamb. 1997. Increased GCSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp. Hematol. 25: 122-131.
15. Jiao, H., W. Yang, K. Berrada, M. Tabrizi, L. Shultz, and T. Yi. 1997. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp. Hematol. 25: 592-600.
16. Miwa, K., M. Asano, R. Horai, Y. Iwakura, S. Nagata, and T. Suda. 1998. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4: 1287-1292.
17. Daigle, I., S. Yousefi, M. Colonna, D. R. Green, and H. U. Simon. 2002. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat. Med. 8: 61-67.
18. Kruger, J., J. R. Butler, V. Cherapanov, Q. Dong, H. Ginzberg, A. Govindarajan, S. Grinstein, K. A. Siminovitch, and G. P. Downey. 2000. Deficiency of Src homology 2-containing phosphatase 1 results in abnormalities in murine neutrophil function: studies in motheaten mice. J. Immunol. 165: 5847-5859.
19. Lucas, M., and F. Solano. 1992. Coelenterazine is a superoxide anionsensitive chemiluminescent probe: its usefulness in the assay of respiratory burst in neutrophils. Anal. Biochem. 206: 273-277.
20. Ichinohe, T., H. K. Lee, Y. Ogura, R. Flavell, and A. Iwasaki. 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206: 79-87.
21. Allen, I. C., M. A. Scull, C. B. Moore, E. K. Holl, E. McElvania-TeKippe, D. J. Taxman, E. H. Guthrie, R. J. Pickles, and J. P. Ting. 2009. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30: 556-565.
22. Thomas, P. G., P. Dash, J. R. Aldridge, Jr., A. H. Ellebedy, C. Reynolds, A. J. Funk, W. J. Martin, M. Lamkanfi, R. J. Webby, K. L. Boyd, et al. 2009. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30: 566-575.
23. Dostert, C., V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.
24. Larsen, C. M., M. Faulenbach, A. Vaag, A. Vølund, J. A. Ehses, B. Seifert, T. Mandrup-Poulsen, and M. Y. Donath. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356: 1517-1526.
25. Dinarello, C. A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27: 519-550.
26. Greten, F. R., M. C. Arkan, J. Bollrath, L. C. Hsu, J. Goode, C. Miething, S. I. Göktuna, M. Neuenhahn, J. Fierer, S. Paxian, et al. 2007. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931.
27. Coeshott, C., C. Ohnemus, A. Pilyavskaya, S. Ross, M. Wieczorek, H. Kroona, A. H. Leimer, and J. Cheronis. 1999. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad. Sci. USA 96: 6261-6266.
28. Jia, S. H., J. Parodo, A. Kapus, O. D. Rotstein, and J. C. Marshall. 2008. Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8. J. Biol. Chem. 283: 5402-5413.
29. Boldin, M. P., E. E. Varfolomeev, Z. Pancer, I. L. Mett, J. H. Camonis, and D. Wallach. 1995. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270: 7795-7798.
30. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
31. Holler, N., R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider, B. Seed, and J. Tschopp. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1: 489-495.
32. Segal, A. W. 2005. How neutrophils kill microbes. Annu. Rev. Immunol. 23: 197-223.
33. Fuchs, T. A., U. Abed, C. Goosmann, R. Hurwitz, I. Schulze, V. Wahn, Y. Weinrauch, V. Brinkmann, and A. Zychlinsky. 2007. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176: 231-241.
34. Engelich, G., M. White, and K. L. Hartshorn. 2001. Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J. Leukoc. Biol. 69: 50-56.
35. Centola, M., G. Wood, D. M. Frucht, J.Galon, M. Aringer, C. Farrell, D. W. Kingma, M. E. Horwitz, E. Mansfield, S. M. Holland, et al. 2000. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95: 3223-3231.
36. Batliwalla, F. M., W. Li, C. T. Ritchlin, X. Xiao, M. Brenner, T. Laragione, T. Shao, R. Durham, S. Kemshetti, E. Schwarz, et al. 2005. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. 11: 21-29.
37. Christophi, G. P., C. A. Hudson, R. C. Gruber, C. P. Christophi, C. Mihai, L. J. Mejico, B. Jubelt, and P. T. Massa. 2008. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab. Invest. 88: 243-255.
38. Honorat, J. F., A. Ragab, L. Lamant, G. Delsol, and J. Ragab-Thomas. 2006. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107: 4130-4138.
39. Han, Y., H. M. Amin, B. Franko, C. Frantz, X. Shi, and R. Lai. 2006. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108: 2796-2803.
40. Oka, T., M. Ouchida, M. Koyama, Y. Ogama, S. Takada, Y. Nakatani, T. Tanaka, T. Yoshino, K. Hayashi, N. Ohara, et al. 2002. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62: 6390-6394.
41. Oka, T., T. Yoshino, K. Hayashi, N. Ohara, T. Nakanishi, Y. Yamaai, A. Hiraki, C. A. Sogawa, E. Kondo, N. Teramoto, et al. 2001. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am. J. Pathol. 159: 1495-1505.